Literature DB >> 34292953

Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder.

Young H Lee1, Molly M Lee1, Dinuka M De Silva1, Arpita Roy1, Cara E Wright1, Tiffany K Wong1, Rene Costello2, Oluwole Olaku1, Robert L Grubb3, Piyush K Agarwal1, Andrea B Apolo2, Donald P Bottaro1.   

Abstract

Comprehensive characterizations of bladder cancer (BCa) have established molecular phenotype classes with distinct alterations and survival trends. Extending these studies within the tyrosine kinase (TK) family to identify disease drivers could improve our use of TK inhibitors to treat specific patient groups or individuals. We examined the expression distribution of TKs as a class (n = 89) in The Cancer Genome Atlas (TCGA) muscle invasive BCa data set (n >400). Patient profiles of potentially oncogenic alterations (overexpression and/or amplification) clustered TKs into 3 groups; alterations of group 1 and 3 TKs were associated with significantly worse patient survival relative to those without alterations. Many TK pathways induce epithelial-to-mesenchymal transition (EMT), which promotes tumor invasiveness and metastasis. Overexpression and/or amplification among 9 EMT transcriptional activators occurred in 43% of TCGA cases. Co-occurring alterations of TKs and EMT transcriptional activators involved most group 1 TKs; 24% of these events were associated with significantly worse patient survival. Co-occurring alterations of receptor TKs and their cognate ligands occurred in 16% of TCGA cases and several BCa-derived cell lines. Suppression of GAS6, MST1 or CSF1, or their respective receptors (AXL, MST1R and CSF1R), in BCa cell lines was associated with decreased receptor activation, cell migration, cell proliferation and anchorage independent cell growth. These studies reveal the patterns and prevalence of potentially oncogenic TK pathway-related alterations in BCa and identify specific alterations associated with reduced BCa patient survival. Detection of these features in BCa patients could better inform TK inhibitor use and improve clinical outcomes.

Entities:  

Year:  2021        PMID: 34292953     DOI: 10.1371/journal.pone.0241766

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  53 in total

Review 1.  Phosphatidylserine Is the Signal for TAM Receptors and Their Ligands.

Authors:  Greg Lemke
Journal:  Trends Biochem Sci       Date:  2017-07-19       Impact factor: 13.807

Review 2.  TAM receptor signaling in immune homeostasis.

Authors:  Carla V Rothlin; Eugenio A Carrera-Silva; Lidia Bosurgi; Sourav Ghosh
Journal:  Annu Rev Immunol       Date:  2015-01-14       Impact factor: 28.527

3.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

Authors:  Padmanee Sharma; Margitta Retz; Arlene Siefker-Radtke; Ari Baron; Andrea Necchi; Jens Bedke; Elizabeth R Plimack; Daniel Vaena; Marc-Oliver Grimm; Sergio Bracarda; José Ángel Arranz; Sumanta Pal; Chikara Ohyama; Abdel Saci; Xiaotao Qu; Alexandre Lambert; Suba Krishnan; Alex Azrilevich; Matthew D Galsky
Journal:  Lancet Oncol       Date:  2017-01-26       Impact factor: 41.316

4.  Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.

Authors:  Eugene J Pietzak; Aditya Bagrodia; Eugene K Cha; Esther N Drill; Gopa Iyer; Sumit Isharwal; Irina Ostrovnaya; Priscilla Baez; Qiang Li; Michael F Berger; Ahmet Zehir; Nikolaus Schultz; Jonathan E Rosenberg; Dean F Bajorin; Guido Dalbagni; Hikmat Al-Ahmadie; David B Solit; Bernard H Bochner
Journal:  Eur Urol       Date:  2017-06-03       Impact factor: 20.096

5.  Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.

Authors:  Philip H Kim; Eugene K Cha; John P Sfakianos; Gopa Iyer; Emily C Zabor; Sasinya N Scott; Irina Ostrovnaya; Ricardo Ramirez; Arony Sun; Ronak Shah; Alyssa M Yee; Victor E Reuter; Dean F Bajorin; Jonathan E Rosenberg; Nikolaus Schultz; Michael F Berger; Hikmat A Al-Ahmadie; David B Solit; Bernard H Bochner
Journal:  Eur Urol       Date:  2014-08-01       Impact factor: 20.096

6.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

Authors:  Arjun V Balar; Matthew D Galsky; Jonathan E Rosenberg; Thomas Powles; Daniel P Petrylak; Joaquim Bellmunt; Yohann Loriot; Andrea Necchi; Jean Hoffman-Censits; Jose Luis Perez-Gracia; Nancy A Dawson; Michiel S van der Heijden; Robert Dreicer; Sandy Srinivas; Margitta M Retz; Richard W Joseph; Alexandra Drakaki; Ulka N Vaishampayan; Srikala S Sridhar; David I Quinn; Ignacio Durán; David R Shaffer; Bernhard J Eigl; Petros D Grivas; Evan Y Yu; Shi Li; Edward E Kadel; Zachary Boyd; Richard Bourgon; Priti S Hegde; Sanjeev Mariathasan; AnnChristine Thåström; Oyewale O Abidoye; Gregg D Fine; Dean F Bajorin
Journal:  Lancet       Date:  2016-12-08       Impact factor: 79.321

7.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Thomas Powles; Mauricio Burotto; Bernard Escudier; Maria T Bourlon; Bogdan Zurawski; Victor M Oyervides Juárez; James J Hsieh; Umberto Basso; Amishi Y Shah; Cristina Suárez; Alketa Hamzaj; Jeffrey C Goh; Carlos Barrios; Martin Richardet; Camillo Porta; Rubén Kowalyszyn; Juan P Feregrino; Jakub Żołnierek; David Pook; Elizabeth R Kessler; Yoshihiko Tomita; Ryuichi Mizuno; Jens Bedke; Joshua Zhang; Matthew A Maurer; Burcin Simsek; Flavia Ejzykowicz; Gisela M Schwab; Andrea B Apolo; Robert J Motzer
Journal:  N Engl J Med       Date:  2021-03-04       Impact factor: 91.245

8.  The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Authors:  Julie Earl; Daniel Rico; Enrique Carrillo-de-Santa-Pau; Benjamín Rodríguez-Santiago; Marinela Méndez-Pertuz; Herbert Auer; Gonzalo Gómez; Herbert Barton Grossman; David G Pisano; Wolfgang A Schulz; Luis A Pérez-Jurado; Alfredo Carrato; Dan Theodorescu; Stephen Chanock; Alfonso Valencia; Francisco X Real
Journal:  BMC Genomics       Date:  2015-05-22       Impact factor: 3.969

9.  Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.

Authors:  Jonathan E Rosenberg; Peter H O'Donnell; Arjun V Balar; Bradley A McGregor; Elisabeth I Heath; Evan Y Yu; Matthew D Galsky; Noah M Hahn; Elaina M Gartner; Juan M Pinelli; Shang-Ying Liang; Amal Melhem-Bertrandt; Daniel P Petrylak
Journal:  J Clin Oncol       Date:  2019-07-29       Impact factor: 44.544

10.  COSMIC: the Catalogue Of Somatic Mutations In Cancer.

Authors:  John G Tate; Sally Bamford; Harry C Jubb; Zbyslaw Sondka; David M Beare; Nidhi Bindal; Harry Boutselakis; Charlotte G Cole; Celestino Creatore; Elisabeth Dawson; Peter Fish; Bhavana Harsha; Charlie Hathaway; Steve C Jupe; Chai Yin Kok; Kate Noble; Laura Ponting; Christopher C Ramshaw; Claire E Rye; Helen E Speedy; Ray Stefancsik; Sam L Thompson; Shicai Wang; Sari Ward; Peter J Campbell; Simon A Forbes
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.